RESUME PAGE *

HIMANSHU R. PATEL, DO

HIMANSHU R. PATEL, DO

**** ********* ** ******, ** 75230

214-***-**** acf0hg@r.postjobfree.com

Board Certified Rheumatologist with over 12 years of experience evaluating and treating patients, training and supervising

physicians and staff, and performing clinical research into rheumatoid arthritis, lupus, psoriatic arthritis, and gout. Intelligent,

meticulous and adaptive, as well as ready for transition into the pharmaceutical or biotech industry.

EXPERIENCE

FREEDOM HEALTH CENTERS McKinney, TX

Medical Director 2013 Present

ARTHRITIS CENTERS OF TEXAS Dallas, TX

Rheumatologist and Lead Partner 2005 Present

KINGS DAUGHTERS CLINIC Temple, TX

Rheumatologist 2003 2005

SPRING BRANCH MEDICAL CENTER Houston, TX

Rheumatologist 2002 2003

DARTMOUTH HITCHCOCK MEDICAL CENTER Lebanon, NH

Fellow, Rheumatology 2000 2002

● Treatment of Gout – Prospective Study 2000 2002

● Study of New Onset Rheumatoid Arthritis Observational Study 2001 2002

OSTEOPATHIC MEDICAL CENTER Fort Worth, TX

AKRON CITY HOSPITAL Akron, OH

Resident, Internal Medicine 1997 2000

EDUCATION

WESTERN UNIVERSITY OF HEALTH SCIENCES Pomona, CA

Doctorate of Osteopathic Medicine 1997

UNIVERSITY OF TEXAS AT AUSTIN Austin, TX

Bachelor of Arts, Biology 1993

PROFESSIONAL ACTIVITIES

Licensure: Licensed to Practice Medicine in the State of Texas

Certification: Board Certified in Internal Medicine and Rheumatology

Certified: Institute of Functional Medicine (2011), Dale Carnegie Course (2012), Age

Management Medicine Education Foundation and Medicine Group (2013)

Memberships: ACR, North Texas Rheumatology Society, Dallas County Medical Society, ACOI, AOA

Presentations: Ongoing Resident Lecture teaching series, Baylor University Medical Center

Speaker Bureau AbbVie Pharmaceuticals, 2009 2014

Speaker Bureau Pfizer Pharmaceuticals, 2005 2007

Speaker Bureau Wyeth Pharmaceuticals, 2004 2006

Publications:

Patel, H.R., Brown, L.A., Rigby W. "Assessment of Cholesterol Levels & Other Cardiovascular

Disease Risk Factors Influencing Ischemic Complications of Giant Cell Arteritis," Arthritis Rheum

2002:46S & ACR Poster Presentation.

RESUME PAGE 2

HIMANSHU R. PATEL, DO

Agrawal, N., Patel, H.R., Brum, A.M. "Alterations of C fos by light/dark in Rds mouse retina:

Possible involvement in apoptosis of photoreceptors." Ophthalmology and Visual Sciences 1995,

36:4:3 15.

CLINICAL TRIALS PERFORMED

Ongoing studies:

● A multicentre, randomized, double blind, placebo controlled, parallel group study of the effect of fostamatinib 100

mg twice daily on 24 hour ambulatory blood pressure in patients with RA – primary investigator

● A multicenter, open label, single arm study to evaluate the safety of administering rituximab at a more rapid

infusion rate in patients with RA – sub investigator

● A randomized, double blind, placebo controlled, multicenter study of secunumab to demonstrate the efficacy at 24

weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active psoriatic

arthritis – sub investigator

● A multicenter, double blind, randomized, parallel arm study to determine the effect of methotrexate dose on clinical

outcome and ultrasonographic signs in subjects with moderately to severely active rheumatoid arthritis treated with

adalimumab – sub investigator

● A long term extension study to assess the safety and efficacy of fostamatinib disodium in the treatment of

rheumatoid arthritis primary investigator

● A phase III, multi centre, randomized, double blind, placebo controlled, parallel group study of two dosing regimens

of fostamatinib disodium in rheumatoid arthritis patients with an inadequate response to DMARDS – primary

investigator

● A Randomized, Placebo Controlled, Double Blind, Parallel Group International Study to Evaluate the Safety and

Efficacy of Rituximab in Combination with Methotrexate, Compared to Methotrexate Monotherapy, in Patients

with Active RA Phase 3– Principal Investigator

● Open Label Continuation Trial of Investigational Drug in Subjects With Systemic Lupus Erythematosus (SLE) –

Sub Investigator

● A Randomized, Head to Head, Single Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept

versus Subcutaneous Adalimumab, Both with Background Methotrexate, in Biologic naïve Subjects with

Rheumatoid Arthritis – Sub Investigator

Previous studies:

● A Phase 3b Study to Evaluate the Safety of Investigational Drug in Subjects who Switch from IV to SQ Therapy

Sub Investigator

● A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in

Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept or

Adalimumab – Sub Investigator

● An Open Label, Prospective Study of the Safety of Investigational Drug in Combination with Other

Disease Modifying Anti Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis – Sub Investigator

● A double blind, randomized, parallel arm, multicenter study to determine the dose response of methotrexate in

combination therapy with adalimumab in subjects with early rheumatoid arthritis sub investigator

● Phase 3, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of 2 Doses of

Investigational Drug in Patients with Active Rheumatoid Arthritis on Background Methotrexate with Inadequate

Response to TNF Inhibitors – Sub Investigator

● An Open Label, Randomized Study to Evaluate the Safety, Tolerability and Efficacy of Investigational Drug

Monotherapy or Investigational Drug in Combination with non biologic DMARDS in Patients with Active

Rheumatoid Arthritis Who Have an Inadequate Response to Current non biologic or Biologic DMARDS – Sub

Investigator

● A Long Term, Open Label Follow Up Study of Investigational Drug for the Treatment of Rheumatoid Arthritis –

Sub Investigator

RESUME PAGE 3

HIMANSHU R. PATEL, DO

● A Phase 2 Study to Evaluate the Efficacy and Safety of Investigational Drug in Combination with Methotrexate

Compared with Inflixamab plus Methotrexate in Patients with Active Rheumatoid Arthritis Currently Responding

Inadequately to Etanercept or Adalimumab Sub Investigator

CLINICAL TRIALS, CONTINUED PREVIOUS STUDIES:

● A Study to Evaluate the Safety and Efficacy of Investigational Drug Compared to Placebo in Patients with Active

Rheumatoid Arthritis Continuing Methotrexate Treatment – Sub Investigator

● A Study to Evaluate the Safety and Efficacy of Investigational Drug Compared to Placebo in Patients with Active

Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti TNF Therapy – Sub Investigator

● Open Label Continuation Trial of Investigational Drug in Subjects With Rheumatoid Arthritis (RA) – Sub

Investigator

● A Study to Evaluate Investigational Drug in Combination With Methotrexate Compared to Methotrexate Alone in

Patients With Rheumatoid Arthritis – Sub Investigator

● Open Label Long Term Safety Study of Investigational Drug for Patients With Rheumatoid Arthritis Sub

Investigator

● A Study of Investigational Drug in Subjects with Dry Mouth Associated with Sjögren’s Syndrome Sub Investigator

● A Study in Subjects with End Stage Joint Disease to Compare the Frequency of Constipation Symptoms in

Subjects Treated with Investigational Drug IR and Oxycodone IR Using a Bowel Function Patient Diary Sub

Investigator

● Randomized, Double Blind, Parallel Group, Placebo Controlled Multicenter Study Evaluating the Efficacy of

Investigational Drug and Celecoxib 200 mg QD in Patients with Osteoarthritis of the Knee – Sub Investigator

● A Randomized, Double Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of

Investigational Drug in Combination with Methotrexate compared to Methotrexate Alone in Methotrexate Naïve

Patients with Active Rheumatoid Arthritis – Sub Investigator

● A Phase III, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and

Safety of Investigational Drug vs Placebo in Subjects with Active Rheumatoid Arthritis on Background DMARDS

Who Have Failed Anti TNF Therapy – Sub Investigator

● A Phase III, Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Use Study to Evaluate the Safety

and Tolerability of Investigational Drug Administered Intravenously to Subjects with Active

● Rheumatoid Arthritis With or Without Medical Co Morbidities Receiving Disease Modifying Anti Rheumatic

Drugs and/or Biologics Approved for RA – Sub Investigator

● A randomized, double blind, parallel group study of safety and the effect on clinical outcome of tocilizumab SC

versus placebo SC in combination with traditional disease modifying anti rheumatic drugs in patients with moderate

to severe active rheumatoid arthritis.

● A randomized, parallel group, open label, multicenter study to evaluate the effects of tocilizumab on vaccination in

subjects with active rheumatoid arthritis receiving background methotrexate.

Contact this candidate